Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169532 · ClinicalTrials.gov registry record · Phase 1
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01169532 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 16 participants.
The verdict
NCT01169532, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of giving ridaforolimus and vorinostat together in treating patients with advanced solid tumors or lymphoma. Giving ridaforolimus in combination with vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- DRUG vorinostat
- OTHER pharmacological study
- DRUG ridaforolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01169532
The ClinicalTrials.gov registry entry for NCT01169532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01169532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01169532 about?
NCT01169532 is a clinical study titled "Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma". This phase I trial is studying the side effects and best dose of giving ridaforolimus and vorinostat together in treating patients with advanced solid tumors or lymphoma. Giving ridaforolimus in combination with vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed fo...
What is the current status of trial NCT01169532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-10. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01169532?
The interventions under investigation include: laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), vorinostat (DRUG), pharmacological study (OTHER), ridaforolimus (DRUG).
Who is sponsoring clinical trial NCT01169532?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.